Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $55 | $143 | $144 | $230 |
| Short-Term Investments | $47 | $0 | $30 | $0 |
| Receivables | $0 | $0 | $3 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $5 | $3 | $3 |
| Total Curr. Assets | $104 | $148 | $181 | $233 |
| Property Plant & Equip (Net) | $0 | $1 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $1 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $105 | $148 | $181 | $233 |
| Liabilities | – | – | – | – |
| Payables | $0 | $1 | $0 | $1 |
| Short-Term Debt | $0 | $15 | $1 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $6 | $0 | $0 | $0 |
| Other Curr. Liab. | $12 | $6 | $14 | $11 |
| Total Curr. Liab. | $19 | $22 | $15 | $12 |
| LT Debt | $15 | $0 | $15 | $16 |
| Deferred Rev, NC | $0 | $6 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $15 | $6 | $15 | $16 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $0 | $0 |
| Total Liabilities | $34 | $29 | $30 | $27 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$450 | -$394 | -$357 | -$295 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $521 | $514 | $508 | $500 |
| Total Equity | $71 | $120 | $151 | $206 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $105 | $148 | $181 | $233 |
| Net Debt | -$39 | -$127 | -$128 | -$214 |